QIAGEN (QGEN) Form 144 Discloses Insider Sales Totaling 50,000 Shares
Rhea-AI Filing Summary
Form 144 filed for QIAGEN N.V. (QGEN) reports a proposed sale of 18,577 common shares with an aggregate market value of $910,286, to be sold on 08/14/2025 on the NYSE. The filing lists total outstanding shares of 216,556,000, and shows the securities were acquired as performance shares on 02/21/2023 (9,756 shares), 02/27/2025 (4,736 shares) and 02/28/2025 (4,085 shares). The form also discloses two sales on 08/13/2025 by Roland Sackers totaling 50,000 shares for combined gross proceeds of $2,456,435.00. The filer signs the standard attestation that no material nonpublic information is known.
Positive
- Complete transaction details are provided including broker, sale dates, and aggregate market values which improves transparency.
- Acquisition history is disclosed (dates and number of performance shares), supporting Rule 144 requirements.
Negative
- Insider selling is disclosed: 18,577 shares proposed and 50,000 shares sold recently, which could be perceived negatively by some investors.
- Some filer metadata is blank or not provided (CIK/complete contact fields appear missing), reducing administrative completeness.
Insights
TL;DR: Routine insider sale disclosure; size is immaterial relative to outstanding shares.
The filing shows a proposed sale of 18,577 shares valued at $910,286 against 216.556 million shares outstanding, representing roughly 0.0086% of the outstanding shares, which is immaterial to market capitalization. Recent reported sales of 50,000 shares on 08/13/2025 produced $2.46 million in proceeds; that volume equals about 0.023% of outstanding stock. These disclosures are required and increase transparency but do not indicate material change to capitalization or control.
TL;DR: Filing appears compliant with Rule 144 requirements and includes standard attestation.
The form provides acquisition details (dates and nature: performance shares) and lists broker and sale dates, satisfying Rule 144 disclosure elements. The signer affirms no material nonpublic information is known; there is no indication in the filing of any trading-plan adoption or exception. From a compliance standpoint the document contains the necessary information for public notice of intended insider sales.
FAQ
What does the QGEN Form 144 disclose about the proposed sale?
What were the acquisition sources and dates for the securities to be sold?
Who is the broker handling the proposed sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.